Navigation Links
MiMedx Group, Inc. to Present at the 10th Annual Needham Healthcare Conference
Date:3/16/2011

MARIETTA, Ga., March 16, 2011 /PRNewswire/ -- MiMedx Group, Inc. (OTC Bulletin Board: MDXG), an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that it will present at the 10th Annual Needham Healthcare Conference in New York.  Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO of MiMedx, and John Daniel, President of Surgical Biologics, a wholly-owned subsidiary of MiMedx, are scheduled to present on Wednesday, April 6th, at 10:00 a.m. Eastern Time at the New York Palace Hotel in New York City.  A webcast of this presentation will be available on the Company's website, www.mimedx.com.  

About the Company

MiMedx is an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and bioimplants manufactured from human amniotic membrane. The Company is successfully emerging from a development-focused start-up into a fully integrated operating company with an experienced team poised to capitalize on its science and technology to generate rapid sales growth and profitability.  Our mantra is "Repair, don't replace" because our biochemists, engineers, designers and physicians believe it is better to augment repair when possible rather than replace traumatized, but otherwise healthy tissues and structures.  Our platform technologies, HydroFix™ and CollaFix™, and our newest platform technology, Purion® developed by our wholly-owned subsidiary, Surgical Biologics, have a vast number of potential applications in treating traumatized tissue and structures and MiMedx is focused on commercializing multiple applications for the Company's three technology platforms. In parallel, we are seeking strategic relationships, in selective categories, to more rapidly commercialize our technologies.  


'/>"/>
SOURCE MiMedx Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. MiMedx Announces Launch of AmnioFix™
2. MiMedx to Attend American Academy of Orthopedic Surgeons Annual Meeting
3. MiMedx Group, Inc. to Present at the 13th Annual Needham Growth Conference
4. MiMedx Group, Inc. Announces Release Date For Third Quarter Results
5. MiMedx Group, Inc. to Present at Noble Financial Sixth Annual Equity Conference
6. MiMedx Group Announces Temporary Trading Symbol Designation
7. Apexigen Announces the Filing by its Partner, Simcere Pharmaceutical Group, of First IND
8. Photonic Products Group, Inc. Announces New Sales and Marketing VP
9. Encorium Group, Inc. Announces New Business Contract Wins of $6.8 Million, Including Two Pivotal Phase III Studies for a Major Asian Technology Company
10. Anpath Group, Inc. Announces Fiscal 2010 Third Quarter Results
11. Encorium Group, Inc. Announces One-for-Eight Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Dutch philosopher Koert van Mensvoort ... Nature, at the University of Technology in Eindhoven - has written a ... letter, he calls on humanity to avoid becoming a slave and victim to ... ... Dutch philosopher Koert van Mensvoort – founder of the Next ...
(Date:4/20/2017)... 2017 For today, Stock-Callers.com redirects investors, ... development and clinical research aimed at treating diseases and medical ... Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Kite Pharma Inc. (NASDAQ: KITE), ... can access our complimentary research reports on these stocks now ... http://stock-callers.com/registration ...
(Date:4/19/2017)... Ca (PRWEB) , ... April 18, 2017 , ... A ... technological advances. This webinar, which is part of the Protein and Cell Analysis ... Cytometer and outline where this technology fits in current and future applications. , ...
(Date:4/19/2017)... ... April 18, 2017 , ... ... Labs . The move comes after the company changed focus to making analytical ... new brand and our new technology,” says CEO Robert Hart. Founders Bernardo Cordovez, ...
Breaking Biology Technology:
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
Breaking Biology News(10 mins):